Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO‐DB SHIP consortium
Open Access
- 4 February 2022
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 197 (6) , 755-765
Abstract
Summary: As treatments for second relapsed and refractory first relapsed paediatric AML transition from purely palliative to more commonly curative in nature, comparative data is necessary for evaluating the effectiveness of emerging treatment options. Furthermore, little is known about predictors of prognosis following third‐line therapy. From 2004 until 2019, 277 of the 869 patients enrolled in NOPHO‐DB SHIP consortium trials experienced a first relapse and, of these patients, 98 experienced refractory first relapse and 59 a second relapse. Data on patient and disease characteristics within this cohort of 157 patients was analysed to determine probability of overall survival (pOS) and to identify factors influencing survival. Data on early treatment response and complete remission were not available. One and 5‐year pOS were 22 ± 3% and 14 ± 3%, respectively. There was no statistically significant difference in survival between refractory first relapsed and second relapsed AML. Factors influencing prognosis included: late relapse, type of third‐line treatment, FLT3 mutational status, and original treatment protocol. These data provide a baseline for evaluating the effectiveness of emerging therapies for the treatment of children with refractory first relapsed and second relapsed paediatric AML and evidence that select patients receiving third‐line therapy can be cured.Keywords
This publication has 23 references indexed in Scilit:
- Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study GroupJournal of Clinical Oncology, 2013
- Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panelBlood, 2012
- Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004Blood, 2012
- Pediatric acute myeloid leukemiaExpert Review of Anticancer Therapy, 2012
- Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium studyPediatric Blood & Cancer, 2010
- Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II studyBritish Journal of Haematology, 2010
- Clinical implications of FLT3 mutations in pediatric AMLBlood, 2006
- Improved outcome after relapse in children with acute myeloid leukaemiaBritish Journal of Haematology, 2006
- Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samplesLeukemia, 2006
- Long-term results in children with AML: NOPHO-AML Study Group – report of three consecutive trialsLeukemia, 2005